Dianthus Therapeutics vs MiniMed Group

Dianthus Therapeutics (DNTH), health care, and MiniMed Group (MMED), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

MiniMed Group is worth $5B on the stock market and Dianthus Therapeutics $4.9B: MiniMed Group is valued at 2% more. Dianthus Therapeutics's operating margin in its latest fiscal year was -8739% and MiniMed Group's -6.13%. Over the past year Dianthus Therapeutics's share price has moved +119% and MiniMed Group's +0.87%.

Key facts

Dianthus Therapeutics market value
$4.9B
MiniMed Group market value
$5B
Dianthus Therapeutics revenue
$2MFY to 2025-12-31
MiniMed Group revenue
$3.1BFY to 2026-04-24
Superinvestors holding both
0

Market values as of .

Dianthus Therapeutics vs MiniMed Group: every measure side by side
Measure Dianthus Therapeutics MiniMed Group
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312026-04-24
Size
Market cap$4.9Blower$5Bhigher
Revenue$2Mlower$3.1Bhigher
Earnings-$162.3Mhigher-$333Mlower
Employees92lower8,000higher
Total assets$530.9Mlower$4.6Bhigher
Valuation
P/E——
P/S2406higher1.6lower
P/B3.9higher1.4lower
Dividend yield0.00%0.00%
Profitability
Operating margin-8739%lower-6.13%higher
Balance sheet
Net assets$493.4Mlower$3.6Bhigher
Total liabilities$37.5Mlower$1Bhigher
Total debt——
Cash on hand$51.1Mlower$298Mhigher
Price change
Today-2.87%higher-4.66%lower
1 year+119%higher+0.87%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Dianthus Therapeutics only (2)

MiniMed Group only (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio. Who owns DNTH

Further comparisons

Learn

Questions and answers

Which is bigger, Dianthus Therapeutics or MiniMed Group?

By market value, MiniMed Group is the larger: $5B against $4.9B for Dianthus Therapeutics. By revenue in its latest fiscal year, MiniMed Group is the larger: $3.1B against $2M for Dianthus Therapeutics.

Which has the higher operating margin?

MiniMed Group: -6.13%, against -8739% for Dianthus Therapeutics. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Dianthus Therapeutics and MiniMed Group?

None of the tracked superinvestors holds both in their latest 13F filing. 2 hold Dianthus Therapeutics and 0 hold MiniMed Group.

Cite this page

Funkfolio, “Dianthus Therapeutics vs MiniMed Group”, data as of 18 November 2026. https://funkfolio.com/compare/dnth-vs-mmed

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.